ALFA-1-ANTITRYPSIN IS A PROGNOSTIC RISK OF DEVELOPING PREGNANCY-ASSOCIATED KIDNEY AND UTERINE DISEASES

Authors:

Abstract:

The purpose of the study was to investigate the role of the biomarker of alpha-1-antitrypsinin the the development of pregnancy-associated renal cell carcinoma and pregnancy-associated uterine sarcoma within 1 years (56 weeks) and 35 years after childbirth. Our data proved the diagnostic value of determining the alpha-1-antitrypsin level for detecting cancer diseases, both in pregnant and non-pregnant women. Oncological diseases significantly increase the level of alpha-1-antitrypsin compared to all groups of healthy women. This is especially true for healthy pregnant women with preterm labor, where the increase in alpha-1-antitrypsin level in pathologies is 2.69 times. Using variation series of alpha-1-antitrypsin levels in blood serum of pregnant women with different periods of pregnancy, we created a prognostic risk model for the development of pregnancy-related cancer during the first year and during 35 years after preterm and timely birth, depending on the level of alpha-antitrypsin.

Keywords:

alpha-1-antitrypsinin pregnancy-associated renal cell carcinoma pregnancy-associated uterine sarcoma

References:

1. Azeze GG, Wu L, Alemu BK, Lee WF, Fung LWY, Cheung ECW, et al. Proteomics approach to discovering non-invasive diagnostic biomarkers and understanding the pathogenesis of endometriosis: a systematic review and meta-analysis. J Transl Med. 2024;22(1):685. doi: 10.1186/s12967-024-05474-3.
2. Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, et al. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology. 2017 Dec;71(6):918-925. doi: 10.1111/his.13311.
3. Feng Y, Xu J, Zhou Q, Wang R, Liu N, Wu Y, et al. Alpha-1 Antitrypsin Prevents the Development of Preeclampsia Through Suppression of Oxidative Stress. Front Physiol. 2016;7:176. doi: 10.3389/fphys.2016.00176.
4. Gaeckle NT, Stephenson L, Reilkoff RA. Alpha-1 antitrypsin deficiency and pregnancy. COPD. 2020;17:326-332. doi: 10.1080/15412555.2020.1754778.
5. Guan HB, Wu QJ, Gong TT. Parity and kidney cancer risk: evidence from epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2013; 22: 2345–53. https://doi.org/10.1158/1055-9965.EPI-13-0759-T.
6. Guarnieri G, Achille A, Lococo S, Vianello A. Pregnancy in Alpha 1 Antitrypsin (AAT) Deficiency and the role of intravenous AAT therapy [Letter to the Editor]. Pulmonology. 2022 Jul-Aug;28(4):317-319. doi: 10.1016/j.pulmoe.2022.01.014.
7. Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M, Amant F. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med. 2012;10:86. doi: 10.1186/1741-7015-10-86.
8. Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine Sarcoma Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database. Intern.J.Gynecological cancer. 2016; 26(6): P1098-1104. DOI: 10.1097/IGC.0000000000000720.
9. Komarevtseva IO, Chernykh YuA, Cherednichenko RV, Zielonyi II, Brezhnyeva YuV, Komarevtsev VN, et al. Alpha-1-antitrypsin – a biomarker of antiprotease protection in the prediction of premature birth in COVID-19 and healthy pregnant womens. World Med Biol. 2023;86(4):86-91. doi: 10.26724/2079-8334-2023-4-86-86-91.
10. Korenaga T.K., Tewari K.S. Gynecologic cancer in pregnancy. Gynecol. Oncol. 2020;157:799–809. doi: 10.1016/j.ygyno.2020.03.015.
11. Mandili G, Notarpietro A, Khadjavi A, Allasia M, Battaglia A, Lucatello B, et al. Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel-Lindau patients. Biomarkers. 2018 Mar;23(2):123-130. doi: 10.1080/1354750X.2016.1269132.
12. Masselli G, Bourgioti C. Review of the Imaging Modalities in the Gynecological Neoplasms During Pregnancy. Cancers (Basel). 2025 Feb 28;17(5):838. doi: 10.3390/cancers17050838.
13. Troisi R, Bjørge T, Gissler M, Grotmol T, Kitahara CM, Sæther SMM, et al. The Role of Pregnancy, Perinatal Factors, and Hormones in Maternal Cancer Risk: A review of the evidence. J Intern Med. 2018 Mar 25;283(5):430-445. doi: 10.1111/joim.12747.
14. Wang T, Shuai P, Wang Q, Guo C, Huang S, Li Y, et al. α 1 Antitrypsin is a potential target of inflammation and immunomodulation (Review). Mol Med Rep. 2025 Feb 24;31(4):107. doi: 10.3892/mmr.2025.13472.
15. Xiang S, Yang L, He Y, Ding F, Qiao S, Su Z, et al. Alpha-1 Antitrypsin as a Regulatory Protease Inhibitor Modulating Inflammation and Shaping the Tumor Microenvironment in Cancer. Cells. 2025 Jan 10;14(2):88. doi: 10.3390/cells14020088.

Publication:

«World of Medicine and Biology» Vol. 21 No. 92 (2025) , с. 78-83
УДК 616.61-006:616.65+576.367

DOI:

https://doi.org/10.26724/2079-8334-2025-2-92-78-83